Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients.

Bins S, Basak EA, El Bouazzaoui S, Koolen SLW, Oomen-de Hoop E, van der Leest CH, van der Veldt AAM, Sleijfer S, Debets R, van Schaik RHN, Aerts JGJV, Mathijssen RHJ.

Br J Cancer. 2018 May;118(10):1296-1301. doi: 10.1038/s41416-018-0074-1. Epub 2018 Apr 26.

PMID:
29695768
2.

Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.

de Man FM, Goey AKL, van Schaik RHN, Mathijssen RHJ, Bins S.

Clin Pharmacokinet. 2018 Mar 8. doi: 10.1007/s40262-018-0644-7. [Epub ahead of print] Review.

PMID:
29520731
3.

Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel.

Belderbos BPS, de Wit R, Hoop EO, Nieuweboer A, Hamberg P, van Alphen RJ, Bergman A, van der Meer N, Bins S, Mathijssen RHJ, van Soest RJ.

Oncotarget. 2017 Nov 16;8(63):106468-106474. doi: 10.18632/oncotarget.22474. eCollection 2017 Dec 5.

4.

Influence of Enzalutamide on Cabazitaxel Pharmacokinetics: a Drug-Drug Interaction Study in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients.

Belderbos BPS, Bins S, van Leeuwen RWF, Oomen-de Hoop E, van der Meer N, de Bruijn P, Hamberg P, Overkleeft ENM, van der Deure WM, Lolkema MP, de Wit R, Mathijssen RHJ.

Clin Cancer Res. 2018 Feb 1;24(3):541-546. doi: 10.1158/1078-0432.CCR-17-2336. Epub 2017 Nov 17.

PMID:
29150561
5.

Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study.

Weeber F, Cirkel GA, Hoogstraat M, Bins S, Gadellaa-van Hooijdonk CGM, Ooft S, van Werkhoven E, Willems SM, van Stralen M, Veldhuis WB, Besselink NJM, Horlings HM, Steeghs N, de Jonge MJ, Langenberg MHG, Wessels LFA, Cuppen EPJG, Schellens JH, Sleijfer S, Lolkema MP, Voest EE.

Oncotarget. 2017 Mar 8;8(33):55582-55592. doi: 10.18632/oncotarget.16029. eCollection 2017 Aug 15.

6.

Sorafenib-Induced Changes in Thyroid Hormone Levels in Patients Treated for Hepatocellular Carcinoma.

Beukhof CM, van Doorn L, Visser TJ, Bins S, Visser WE, van Heerebeek R, van Kemenade FJ, de Rijke YB, de Herder WW, Chaker L, Mathijssen RH, Peeters RP.

J Clin Endocrinol Metab. 2017 Aug 1;102(8):2922-2929. doi: 10.1210/jc.2016-4025.

PMID:
28575418
7.

Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide.

Bins S, van Doorn L, Phelps MA, Gibson AA, Hu S, Li L, Vasilyeva A, Du G, Hamberg P, Eskens F, de Bruijn P, Sparreboom A, Mathijssen R, Baker SD.

Clin Transl Sci. 2017 Jul;10(4):271-279. doi: 10.1111/cts.12458. Epub 2017 Mar 31.

8.

Nivolumab for Squamous-Cell Cancer of Head and Neck.

Bins S, van Meerten E, Mathijssen RH.

N Engl J Med. 2017 Feb 9;376(6):595-6. No abstract available.

PMID:
28181785
9.

Individualized Tamoxifen Dose Escalation-Letter.

Koolen SL, Bins S, Mathijssen RH.

Clin Cancer Res. 2016 Dec 15;22(24):6300. No abstract available.

10.

Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study.

Nieuweboer AJ, de Graan AM, Hamberg P, Bins S, van Soest RJ, van Alphen RJ, Bergman AM, Beeker A, van Halteren H, Ten Tije AJ, Zuetenhorst H, van der Meer N, Chitu D, de Wit R, Mathijssen RH; Dutch Uro-Oncology Studygroup (DUOS).

Clin Cancer Res. 2017 Apr 1;23(7):1679-1683. doi: 10.1158/1078-0432.CCR-16-2110. Epub 2016 Oct 4.

11.

Implementation of a Multicenter Biobanking Collaboration for Next-Generation Sequencing-Based Biomarker Discovery Based on Fresh Frozen Pretreatment Tumor Tissue Biopsies.

Bins S, Cirkel GA, Gadellaa-Van Hooijdonk CG, Weeber F, Numan IJ, Bruggink AH, van Diest PJ, Willems SM, Veldhuis WB, van den Heuvel MM, de Knegt RJ, Koudijs MJ, van Werkhoven E, Mathijssen RH, Cuppen E, Sleijfer S, Schellens JH, Voest EE, Langenberg MH, de Jonge MJ, Steeghs N, Lolkema MP.

Oncologist. 2017 Jan;22(1):33-40. doi: 10.1634/theoncologist.2016-0085. Epub 2016 Sep 23.

12.

Capecitabine and the Risk of Fingerprint Loss.

van Doorn L, Veelenturf S, Binkhorst L, Bins S, Mathijssen R.

JAMA Oncol. 2017 Jan 1;3(1):122-123. doi: 10.1001/jamaoncol.2016.2638. No abstract available.

PMID:
27560202
13.

Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients.

Yu H, van Erp N, Bins S, Mathijssen RH, Schellens JH, Beijnen JH, Steeghs N, Huitema AD.

Clin Pharmacokinet. 2017 Mar;56(3):293-303. doi: 10.1007/s40262-016-0443-y.

PMID:
27534647
14.

Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity.

Bins S, Lenting A, El Bouazzaoui S, van Doorn L, Oomen-de Hoop E, Eskens FA, van Schaik RH, Mathijssen RH.

Pharmacogenomics. 2016 Sep;17(14):1483-90. doi: 10.2217/pgs-2016-0063. Epub 2016 Aug 17.

PMID:
27533851
15.

Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients.

Verheijen RB, Bins S, Mathijssen RH, Lolkema MP, van Doorn L, Schellens JH, Beijnen JH, Langenberg MH, Huitema AD, Steeghs N; Dutch Pharmacology Oncology Group.

Clin Cancer Res. 2016 Dec 1;22(23):5738-5746. Epub 2016 Jul 28.

16.

Prospective Analysis in GIST Patients on the Role of Alpha-1 Acid Glycoprotein in Imatinib Exposure.

Bins S, Eechoute K, Kloth JS, de Man FM, Oosten AW, de Bruijn P, Sleijfer S, Mathijssen RH.

Clin Pharmacokinet. 2017 Mar;56(3):305-310. doi: 10.1007/s40262-016-0441-0.

17.

The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies.

Cirkel GA, Weeber F, Bins S, Gadellaa-van Hooijdonk CG, van Werkhoven E, Willems SM, van Stralen M, Veldhuis WB, Ubink I, Steeghs N, de Jonge MJ, Langenberg MH, Schellens JH, Sleijfer S, Lolkema MP, Voest EE.

Ann Oncol. 2016 Aug;27(8):1638-43. doi: 10.1093/annonc/mdw223. Epub 2016 May 27.

PMID:
27234642
18.

Development and clinical validation of an LC-MS/MS method for the quantification of pazopanib in DBS.

Verheijen RB, Bins S, Thijssen B, Rosing H, Nan L, Schellens JH, Mathijssen RH, Lolkema MP, Beijnen JH, Steeghs N, Huitema AD.

Bioanalysis. 2016;8(2):123-34. doi: 10.4155/bio.15.235. Epub 2015 Dec 10.

PMID:
26652864
19.

Conventional dosing of anticancer agents: precisely wrong or just inaccurate?

Bins S, Ratain MJ, Mathijssen RH.

Clin Pharmacol Ther. 2014 Apr;95(4):361-4. doi: 10.1038/clpt.2014.12. No abstract available.

PMID:
24646486
20.

[Drug research in oncology; advances in the genome era].

Bins S, Schellens JH, Voest EE, Sleijfer S.

Ned Tijdschr Geneeskd. 2014;158:A6801. Review. Dutch.

PMID:
24618235
21.

No evidence for diagnostic value of Mallampati score in patients suspected of having obstructive sleep apnea syndrome.

Bins S, Koster TD, de Heij AH, de Vries AC, van Pelt AB, Aarts MC, Rovers MM, van der Heijden GJ.

Otolaryngol Head Neck Surg. 2011 Aug;145(2):199-203. doi: 10.1177/0194599811409302. Epub 2011 May 13. Review.

PMID:
21572078

Supplemental Content

Support Center